For example, co-treating tumor cells that are EGFR T790M and BRAF V600E positive with osimertinib and the BRAF V600E inhibitor encorafenib increased tumor sensitivity compared with encorafenib treatment alone33. The gene discussed is BRAF; the disease is neoplasm.